ArticleNature communications2022
Profiling Fusobacterium infection at high taxonomic resolution reveals lineage-specific correlations in colorectal cancer.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 39 citations in OpenAlex.
- Full-length 16S rRNA nanopore sequencing enables species resolution ofGut microbes · 2026Article
- Pangenome analysis reveals both niche-specific "specialists" and microbial "side hustlers" in colorectal cancer microbiomes.Gut microbes · 2026Article
- Article
- From trees to graphs: rethinking phylogeny in microbiome prediction.Applied and environmental microbiology · 2026Article
- Cross-site oral and esophageal microbiome signatures define diagnostic patterns and reveal mechanistic drivers of ESCC.iScience · 2026Article
- Adaptive graph learning of microbial phylogeny enables accurate and interpretable microbiome-based host phenotype prediction.Applied and environmental microbiology · 2026Article
- Fusobacterium nucleatum-induced mitophagy in macrophages supports intracellular bacterial persistence and promotes esophageal squamous cell carcinoma metastasis.Cellular & molecular immunology · 2026Article
- Article
- Quantification of EctopicInternational journal of molecular sciences · 2026Article
- Integrating ANI and phylogenies for re-evaluation of Fusobacterium taxonomy and disease associations.Nature communications · 2026Article
- Isolation and Characterization of Fusobacterium nucleatum Subspecies from Oral Clinical Specimens.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Reshaping immune cell distribution with mRNA noncationic lipid nanoparticles for overcoming neoadjuvant chemo-immunotherapy resistance.Theranostics · 2026Article
- Taxonomy, carcinogenic mechanisms, and advanced molecular diagnosis of Fusobacterium nucleatum in colorectal cancer: from bench to clinical practice.Frontiers in immunology · 2026Review
- Shifts in the human gut microbiome during cancer chemotherapy are diet-dependent.bioRxiv : the preprint server for biology · 2025Article
- Addressing controversy inGut microbes · 2025Article
- A Modified Method Incorporating Multiplex PCR Reveals Fusobacterium Prevalence in Southern Chinese Population and Its Correlations in Cancers.Microbial biotechnology · 2025Article
- Fusobacterium nucleatum: a transboundary pathogen in host-microbiota networks.Gut pathogens · 2025Review
- Fusobacterium lineage profiling facilitates the clarification of the associations between non-nucleatum Fusobacterium and colorectal cancer.NPJ biofilms and microbiomes · 2025Article
- Advances in research on the intestinal microbiota in the mechanism and prevention of colorectal cancer (Review).Molecular medicine reports · 2025Review
- IntratumoralJournal of oral microbiology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bacterial genus Fusobacterium promotes colorectal cancer (CRC) development, but an understanding of its precise composition at the species level in the human gut and the relevant association with CRC is lacking. Herein, we devise a Fusobacterium rpoB amplicon sequencing (FrpoB-seq) method that enables the differentiation of Fusobacterium species and certain subspecies in the microbiota. By applying this method to clinical tissue and faecal samples from CRC patients, we detect 62 Fusobacterium species, including 45 that were previously undescribed. We additionally reveal that Fusobacterium species may display different lineage-dependent functions in CRC. Specifically, a lineage (designated L1) including F. nucleatum, F. hwasookii, F. periodonticum and their relatives (rather than any particular species alone) is overabundant in tumour samples and faeces from CRC patients, whereas a non-enriched lineage (designated L5) represented by F. varium and F. ulcerans in tumours has a positive association with lymphovascular invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.